HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Roger Giudicelli Pierre Fuentes Pascal Thomas Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barlési, F. Articles by Astoul, P. Search for Related Content PubMed PubMed Citation Articles by Barlési, F. Articles by Astoul, P. Related Collections Lung - cancer

Eur J Cardiothorac Surg 2005;28:629-634
© 2005 Elsevier Science NL

Original articles

Comparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapy

^a Department of Thoracic Oncology, Faculty of Medicine—Assistance Publique Hôpitaux de Marseille, Hôpital Sainte-Marguerite, 13274 Marseille Cedex 09, France
^b Department of Thoracic Surgery, Faculty of Medicine—Assistance Publique Hôpitaux de Marseille, Hôpital Sainte-Marguerite, 13274 Marseille Cedex 09, France
^c Department of Medical Information, Faculty of Medicine—Assistance Publique Hôpitaux de Marseille, Hôpital La Timone, 13005 Marseille Cedex, France

Received 26 May 2005; received in revised form 15 June 2005; accepted 20 June 2005.

^* Corresponding author. Address: Service d'Oncologie Thoracique, Fédération des Maladies Respiratoires, Hôpital Sainte-Marguerite, 270, Bd de Sainte-Marguerite, 13274 Marseille Cedex 09, France. Tel.: +33 491 74 47 36; fax: +33 491 74 55 24. (Email: fabrice.barlesi{at}mail.ap-hm.fr).

Abstract

Objective: Induction Therapy (IT) before surgery emerged as a widely used strategy for IIIAN2 and selected IIIB NSCLC patients. However, IT is associated with a possible increase in postoperative complications. Consequently, selection of patients with the best chances to benefit from combined treatment is mandatory. Methods: Study recorded demographics, treatment and outcome of consecutive patients treated with IT plus surgery for IIIAN2 or IIIB NSCLC. Survival was analysed by Kaplan–Meier and prognostic factors were analysed by log-rank and Cox regression. Results: From 1993 to 2003, 155 patients (IIIAN2=95/IIIB=60) were treated. Complete resection was associated with a significant prolonged median survival both for IIIAN2 (20 vs 16 months, P=0.05) and IIIB (20 vs 15 months, P=0.02) patients. A lower risk of death for IIIAN2 patients was independently associated with postoperative mediastinal lymph node clearance (HR=0.45, 95%CI [0.25–0.81], P=0.009) and absence of postoperative complication (HR=0.54, 95%CI [0.31–0.93], P=0.02). Absence of blood vessel invasion only was identified as an independent predictor of a lower risk of death (HR=0.27, 95%CI [0.12–0.59], P=0.01) for stage IIIB patients. Conclusions: Besides similarities as the role of a complete R0 resection, treatment-related factors influence outcome of IIIAN2 patients while disease-related factors prevail on survival of IIIB patients, in whom the benefit of IT is unclear.

Key Words: Non-small-cell lung cancer • Induction therapy • Surgery • Chemotherapy • Downstaging • Vascular invasion

This article has been cited by other articles:

				T. Gudbjartsson, E. Gyllstedt, A. Pikwer, and P. Jonsson Early surgical results after pneumonectomy for non-small cell lung cancer are not affected by preoperative radiotherapy and chemotherapy. Ann. Thorac. Surg., August 1, 2008; 86(2): 376 - 382. [Abstract] [Full Text] [PDF]

				C. Dooms, E. Verbeken, S. Stroobants, K. Nackaerts, P. De Leyn, and J. Vansteenkiste Prognostic Stratification of Stage IIIA-N2 Non-Small-Cell Lung Cancer After Induction Chemotherapy: A Model Based on the Combination of Morphometric-Pathologic Response in Mediastinal Nodes and Primary Tumor Response on Serial 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography J. Clin. Oncol., March 1, 2008; 26(7): 1128 - 1134. [Abstract] [Full Text] [PDF]

				J. R. Jett, S. E. Schild, R. L. Keith, and K. A. Kesler Treatment of Non-small Cell Lung Cancer, Stage IIIB: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 266S - 276S. [Abstract] [Full Text] [PDF]

				Z. Mansour, E. A. Kochetkova, X. Ducrocq, M.-D. Vasilescu, G. Maxant, A. Buggenhout, J.-M. Wihlm, and G. Massard Induction chemotherapy does not increase the operative risk of pneumonectomy! Eur. J. Cardiothorac. Surg., February 1, 2007; 31(2): 181 - 185. [Abstract] [Full Text] [PDF]